New England Biolabs, Inc.

New England Biolabs, Inc. is a leading manufacturer and supplier of molecular biology products, specializing in reagents, kits, and enzymes for life sciences research. Headquartered in Ipswich, Massachusetts, the company is a for-profit organization registered in SAM.gov that provides advanced research tools to federal agencies, particularly within the National Institutes of Health (NIH) ecosystem. The company focuses on delivering high-quality biological materials used in genomics, infectious disease research, and other critical biomedical investigations, with a primary emphasis on next-generation sequencing technologies and molecular biology research supplies.

Through federal contract awards, New England Biolabs has consistently provided a wide range of specialized products to multiple federal agencies. The company's primary contract deliverables include NEBNext library preparation kits, RNA and DNA sequencing reagents, multiplex oligos for Illumina platforms, PCR reagents, and various enzymatic kits. These products have been procured by agencies such as the National Institute of Allergy and Infectious Diseases (NIAID), National Human Genome Research Institute (NHGRI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Advancing Translational Sciences, and the Centers for Disease Control and Prevention (CDC). Most of these contract awards are standard purchase orders or Blanket Purchase Agreement (BPA) call orders, typically without specific set-aside designations, though some have been designated for total small businesses.

In terms of grant awards, New England Biolabs has participated as a subcontractor on specific research initiatives. A notable example is a sub-grant award from the University of Maryland, Baltimore, where the company contributed to a complex research project involving filarial nematodes. Under this grant, NEB scientists were tasked with examining transcriptomic data, performing RNA interference (RNAi) studies, conducting gene silencing experiments, performing inhibitor studies on filarial nematodes in vitro, assessing phenotypes, confirming transcript reduction through qRT-PCR, and potentially preparing RNA from treated worms for transcriptomic sequencing.

New England Biolabs holds a significant single-award Blanket Purchase Agreement (BPA) with the NIH Office of Logistics and Acquisition Operations, valued at $10,000,000 and effective from January 22, 2024, through January 31, 2026. This IDV authorizes the company to provide a comprehensive range of biological materials, chemicals, and RNA interference items to NIH institutes. Under this BPA, various NIH components, including the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute of Child Health and Human Development (NICHD), have placed task orders. These task orders, typically ranging between $12,000 and $25,000, enable NIH laboratories to efficiently procure essential molecular biology products for genomics research, infectious disease studies, and other critical biomedical investigations.

Created 'by scientists for scientists', New England Biolabs, Inc (NEB) is renowned for consistently providing exceptional product quality and unsurpassed technical support. For over four decades, NEB has been shaping the landscape of bioscience research by discovering, developing and supporting superior research reagents. Today, NEB is the industry leader in the discovery and production of enzymes for molecular biology applications and offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, qPCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis.

NEB is ISO 9001 and ISO 13485 certified.